科华生物
(002022)
| 流通市值：30.75亿 | | | 总市值：30.76亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 387,883,698.3 | 1,759,197,330.48 | 1,350,223,553.61 | 908,526,752.98 |
| 营业收入 | 387,883,698.3 | 1,759,197,330.48 | 1,350,223,553.61 | 908,526,752.98 |
| 二、营业总成本 | 443,013,698.68 | 2,114,186,830.03 | 1,476,366,060.65 | 973,445,721.39 |
| 营业成本 | 242,858,484.69 | 1,111,972,861.71 | 809,534,413.84 | 541,247,222.45 |
| 税金及附加 | 2,642,065.74 | 11,908,612.56 | 8,816,821.81 | 6,650,045.93 |
| 销售费用 | 80,216,690.04 | 433,903,054.3 | 264,541,013.78 | 172,891,851.32 |
| 管理费用 | 70,478,985.28 | 335,947,424.2 | 226,338,098.92 | 146,619,709.08 |
| 研发费用 | 44,061,435.78 | 198,666,101.37 | 147,599,126.1 | 93,537,807.17 |
| 财务费用 | 2,756,037.15 | 21,788,775.89 | 19,536,586.2 | 12,499,085.44 |
| 其中:利息费用 | 5,880,332.97 | 42,229,223.95 | 35,394,425.5 | 24,015,369.67 |
| 其中:利息收入 | 1,693,307.75 | 21,458,947.33 | 18,038,066.8 | 12,450,776.85 |
| 加:公允价值变动收益 | -15,081.75 | -1,172,720.33 | 953,315.21 | 590,817.03 |
| 加:投资收益 | 252,555.56 | 11,973,131.52 | 8,587,932.79 | 7,584,766.34 |
| 资产处置收益 | 1,077,766.1 | 4,208,562.56 | 2,185,685.63 | 1,723,405.4 |
| 资产减值损失(新) | 881,045.4 | -225,183,072.01 | -436,243.91 | -1,111,195.63 |
| 信用减值损失(新) | -4,970,053.18 | -193,754,338.37 | -15,668,028.52 | -6,054,641.88 |
| 其他收益 | 3,886,665.22 | 32,094,361.72 | 22,980,032.21 | 19,793,553.32 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -54,017,103.03 | -726,823,574.46 | -107,539,813.63 | -42,392,263.83 |
| 加:营业外收入 | 65,383.9 | 830,799.12 | 391,904.4 | 228,520.24 |
| 减:营业外支出 | 335,200.44 | 8,852,873.59 | 3,218,684.48 | 1,656,669.99 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -54,286,919.57 | -734,845,648.93 | -110,366,593.71 | -43,820,413.58 |
| 减:所得税费用 | -541,447.6 | -4,198,282.15 | -3,438,049.26 | -6,316,546.84 |
| 六、净利润 | -53,745,471.97 | -730,647,366.78 | -106,928,544.45 | -37,503,866.74 |
| 持续经营净利润 | -53,745,471.97 | -730,647,366.78 | -106,928,544.45 | -37,503,866.74 |
| 归属于母公司股东的净利润 | -53,259,784.78 | -640,601,876.82 | -122,140,657.33 | -52,464,103.69 |
| 少数股东损益 | -485,687.19 | -90,045,489.96 | 15,212,112.88 | 14,960,236.95 |
| (一)基本每股收益 | -0.1 | -1.27 | -0.24 | -0.1 |
| (二)稀释每股收益 | -0.1 | -1.27 | -0.24 | -0.1 |
| 八、其他综合收益 | 11,909,175.59 | -20,195,797.3 | -1,734,692.2 | -9,747,466.32 |
| 归属于母公司股东的其他综合收益 | 11,908,462.46 | -17,044,969.05 | -1,459,628.85 | -7,858,493.21 |
| 九、综合收益总额 | -41,836,296.38 | -750,843,164.08 | -108,663,236.65 | -47,251,333.06 |
| 归属于母公司股东的综合收益总额 | -41,351,322.32 | -657,646,845.87 | -123,600,286.18 | -60,322,596.9 |
| 归属于少数股东的综合收益总额 | -484,974.06 | -93,196,318.21 | 14,937,049.53 | 13,071,263.84 |
| 公告日期 | 2025-04-30 | 2025-04-28 | 2024-10-22 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |